255 research outputs found
VSX J003909.7+611233: a new slowly pulsating B (SPB) star in Cassiopeia?
We report the discovery of a new 13th magnitude variable star in Cassiopeia
close to the variable KP Cas.Analysis of six days of intensive photometry shows
a regular, near sinusoidal modulation with an amplitude of 0.024 mag and a
period of 0.43815(31)d.Although its colour indicates a spectral type around F0
the star probably suffers up to 2−2.5 magnitudes of extinction, so could be an Aor B-type star. Given the period, the low amplitude, the shape of the lightcurve
and the probable spectral type we consider it most likely to be a slowly pulsating
B-type (SPB) star.The variable has been registered in the International Variable
Star Index with the identifier VSX J003909.7+611233
Linear Stability Analysis for Plane-Poiseuille Flow of an Elastoviscoplastic fluid with internal microstructure
We study the linear stability of Plane Poiseuille flow of an
elastoviscoplastic fluid using a revised version of the model proposed by Putz
and Burghelea (Rheol. Acta (2009)48:673-689). The evolution of the
microstructure upon a gradual increase of the external forcing is governed by a
structural variable (the concentration of solid material elements) which decays
smoothly from unity to zero as the stresses are gradually increased beyond the
yield point. Stability results are in close conformity with the ones of a
pseudo-plastic fluid. Destabilizing effects are related to the presence of an
intermediate transition zone where elastic solid elements coexist with fluid
elements. This region brings an elastic contribution which does modify the
stability of the flow
Survey of Period Variations of Superhumps in SU UMa-Type Dwarf Novae
We systematically surveyed period variations of superhumps in SU UMa-type
dwarf novae based on newly obtained data and past publications. In many
systems, the evolution of superhump period are found to be composed of three
distinct stages: early evolutionary stage with a longer superhump period,
middle stage with systematically varying periods, final stage with a shorter,
stable superhump period. During the middle stage, many systems with superhump
periods less than 0.08 d show positive period derivatives. Contrary to the
earlier claim, we found no clear evidence for variation of period derivatives
between superoutburst of the same object. We present an interpretation that the
lengthening of the superhump period is a result of outward propagation of the
eccentricity wave and is limited by the radius near the tidal truncation. We
interpret that late stage superhumps are rejuvenized excitation of 3:1
resonance when the superhumps in the outer disk is effectively quenched. Many
of WZ Sge-type dwarf novae showed long-enduring superhumps during the
post-superoutburst stage having periods longer than those during the main
superoutburst. The period derivatives in WZ Sge-type dwarf novae are found to
be strongly correlated with the fractional superhump excess, or consequently,
mass ratio. WZ Sge-type dwarf novae with a long-lasting rebrightening or with
multiple rebrightenings tend to have smaller period derivatives and are
excellent candidate for the systems around or after the period minimum of
evolution of cataclysmic variables (abridged).Comment: 239 pages, 225 figures, PASJ accepte
The Ninth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the SDSS-III Baryon Oscillation Spectroscopic Survey
The Sloan Digital Sky Survey III (SDSS-III) presents the first spectroscopic
data from the Baryon Oscillation Spectroscopic Survey (BOSS). This ninth data
release (DR9) of the SDSS project includes 535,995 new galaxy spectra (median
z=0.52), 102,100 new quasar spectra (median z=2.32), and 90,897 new stellar
spectra, along with the data presented in previous data releases. These spectra
were obtained with the new BOSS spectrograph and were taken between 2009
December and 2011 July. In addition, the stellar parameters pipeline, which
determines radial velocities, surface temperatures, surface gravities, and
metallicities of stars, has been updated and refined with improvements in
temperature estimates for stars with T_eff<5000 K and in metallicity estimates
for stars with [Fe/H]>-0.5. DR9 includes new stellar parameters for all stars
presented in DR8, including stars from SDSS-I and II, as well as those observed
as part of the SDSS-III Sloan Extension for Galactic Understanding and
Exploration-2 (SEGUE-2).
The astrometry error introduced in the DR8 imaging catalogs has been
corrected in the DR9 data products. The next data release for SDSS-III will be
in Summer 2013, which will present the first data from the Apache Point
Observatory Galactic Evolution Experiment (APOGEE) along with another year of
data from BOSS, followed by the final SDSS-III data release in December 2014.Comment: 9 figures; 2 tables. Submitted to ApJS. DR9 is available at
http://www.sdss3.org/dr
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment
- …